High-dose melphalan and autologous bone marrow transplant as treatment for refractory Hodgkin's disease

Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting.